From this presentation it becomes apparent that preclinical investigation of new drugs is a multi-disciplinary endeavour. The need for close team work between the various scientists is necessary to meet this complex research challenge successfully.
With the development of an ever-increasing number of potent drugs, it is mandatory that the physician responsible for monitoring new drug trials broaden his understanding of preclinical investigations. In doing so, he will soon learn the need for consistent interplay between the preclinical scientist and clinician.
Get full access to this article
View all access options for this article.
References
1.
Division of Pharmacology, Food and Drug Administration, Department of Health, Education and Welfare (1965) Appraisal of the safety of chemicals in foods, drugs and cosmetics. Topeka, Kansas, The Association of Food and Drug Officials of the United States.
2.
GoldenthalE I (1968) Current views on safety evaluation of drugs. FDA Papers, May. Government Printing Office, Washington, DC.
3.
BuyskeD A (1966) The metabolism of drugs. BloSci.16, 702.
4.
TedeschiD HTedeschiR E, (Eds) (1968) The Importance of Fundamental Principles in Drug Evaluation. Raven Press, NY.
5.
PeckH M (1966) Evaluating the safety of drugs. BioSci.16, 696.
6.
BurnsJ JWelchR MConneyA H (1967) Drug effects on enzymes, in Animal and Clinical Pharma. Techniques in Drug Evaluation, Vol. 2, pp 67–75. Year Book Medical Publishers Inc., Chicago.
7.
BrodieB B (1967) Physicochemical and biochemical aspects of pharmacology. J. A. M.A.202, 148.
8.
SanenF JHongE (1969) Comparative biotransformation of drugs in animal and man. Prensa Med. Mex.34, 14.
9.
GarrettE R (1970) The Significance of Properly Designed Preclinical Studies in the Clinical Evaluation of New Drugs. International Journal of Clinical Pharmacology, Therapeutics and Toxicology 6, 20, January 4.
10.
WagnerJ G (1968) Biopharmaceutics influence of formulation on therapeutic activity. Drug Intelligence2, 30, 80, 112, 144.
11.
WagnerJ G (1968) Pharmacokinetics. Drug Intelligence2, 38, 95, 126, 158.
12.
RiegelmanS (1968) Some biological and pharmacokinetic problems in evaluation of dosage forms in animals and in man. Presented at the Research and Development Section, Pharmaceutical Manufacturers Association 20th Annual Meeting, Biloxi, Mississippi, October 20.
13.
MartinC M (1968) Comparative physiological availability of ‘brand’ and ‘generic’ drugs in man. Presented at the Research and Development Section, Pharmaceutical Manufacturers Association 20th Annual Meeting, Biloxi, Mississippi, October 20.
